Continued Administration of Pembrolizumab for Adenocarcinoma of the Lung After the Onset of Fulminant Type 1 Diabetes Mellitus as an Immune‐related Adverse Effect: A Case Report

Thoracic Cancer - Australia
doi 10.1111/1759-7714.13065
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Successful Retreatment Using Pembrolizumab for Non-Small Cell Lung Cancer After Severe Immune-Related Hepatitis: A Case Report

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

A Very Elderly Case of Acute-Onset Autoimmune Type 1 Diabetes Mellitus

Japanese Journal of Geriatrics
GerontologyGeriatrics
2010English

Neuropsychiatric Immune-Related Adverse Events Induced by Pembrolizumab in a Patient With Lung Adenocarcinoma and Systemic Lupus Erythematosus

Internal Medicine
Internal MedicineMedicine
2020English

Immune Checkpoint Inhibitors and Type 1 Diabetes Mellitus: A Case Report and Systematic Review

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2019English

Teplizumab Delays Onset of Type 1 Diabetes Mellitus

Nature Reviews Endocrinology
EndocrinologyMetabolismDiabetes
2019English

Diabetic Ketoacidosis Following Colonoscopy in Fulminant Type 1 Diabetes: A Case Report

The Korean Journal of Medicine
2018English

Type 1 Diabetes Mellitus and Neurofibromatosis 1 : A Rare Association (Case Report)

Journal of Medical Science And clinical Research
2018English

Oxcarbazepine as Monotherapy of Acute Mania in Insufficiently Controlled Type-1 Diabetes Mellitus: A Case-Report

Annals of General Psychiatry
PsychiatryMental Health
2007English

A Case of Fulminant Type 1 Diabetes With Strong Evidence of Autoimmunity

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy